“…In older patients (>30 years), a combination of fludarabine, cyclophosphamide with ATG or alemtuzumab (CAMPATH) is recommended, with a reduction in the cyclophosphamide dose to alleviate toxicity. There is no doubt that bone marrow, rather than mobilised-peripheral blood, is the stem cell source of choice [26]. In the absence of an HLA matched sibling donor, the use of a fully matched-unrelated donor transplant has been shown to be successful [26].…”